BioVie (BIVI) Competitors $1.52 -0.04 (-2.56%) Closing price 04:00 PM EasternExtended Trading$1.50 -0.02 (-1.58%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI vs. IBIO, CARM, ERNA, GOVX, MTNB, SNPX, TAOX, LGVN, SONN, and IXHLShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include iBio (IBIO), Carisma Therapeutics (CARM), Ernexa Therapeutics (ERNA), GeoVax Labs (GOVX), Matinas Biopharma (MTNB), Synaptogenix (SNPX), Synaptogenix (TAOX), Longeveron (LGVN), Sonnet BioTherapeutics (SONN), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry. BioVie vs. Its Competitors iBio Carisma Therapeutics Ernexa Therapeutics GeoVax Labs Matinas Biopharma Synaptogenix Synaptogenix Longeveron Sonnet BioTherapeutics Incannex Healthcare BioVie (NASDAQ:BIVI) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment. Do institutionals & insiders believe in BIVI or IBIO? 4.6% of BioVie shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 2.4% of BioVie shares are owned by company insiders. Comparatively, 0.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings & valuation, BIVI or IBIO? BioVie has higher earnings, but lower revenue than iBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioVieN/AN/A-$17.54M-$79.10-0.02iBio$375K34.20-$24.91MN/AN/A Does the media refer more to BIVI or IBIO? In the previous week, iBio had 3 more articles in the media than BioVie. MarketBeat recorded 3 mentions for iBio and 0 mentions for BioVie. iBio's average media sentiment score of 0.67 beat BioVie's score of 0.00 indicating that iBio is being referred to more favorably in the news media. Company Overall Sentiment BioVie Neutral iBio Positive Which has more risk & volatility, BIVI or IBIO? BioVie has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Do analysts rate BIVI or IBIO? iBio has a consensus price target of $5.00, indicating a potential upside of 544.08%. Given iBio's higher possible upside, analysts plainly believe iBio is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00iBio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BIVI or IBIO more profitable? iBio's return on equity of -73.15% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets BioVieN/A -89.02% -75.32% iBio N/A -73.15%-45.51% SummaryiBio beats BioVie on 8 of the 13 factors compared between the two stocks. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioVieMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.83M$2.49B$5.73B$9.56BDividend YieldN/A1.66%4.53%4.08%P/E Ratio-0.0222.4830.4625.16Price / SalesN/A549.05392.5787.62Price / CashN/A173.7937.0358.50Price / Book0.155.268.956.21Net Income-$17.54M$31.83M$3.26B$265.38M7 Day Performance-8.43%0.82%1.06%-1.13%1 Month Performance-79.21%3.71%4.31%-0.71%1 Year Performance-95.56%9.37%28.39%18.86% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie0.3721 of 5 stars$1.52-2.6%N/A-95.3%$2.83MN/A-0.0210High Trading VolumeIBIOiBio2.1029 of 5 stars$0.74+0.2%$5.00+573.1%-62.8%$12.27M$375K0.00100Gap DownCARMCarisma Therapeutics3.0677 of 5 stars$0.28-4.5%$1.93+590.0%-79.0%$12.20M$19.63M-0.1820News CoverageShort Interest ↓ERNAErnexa Therapeutics0.4461 of 5 stars$1.61+1.6%N/A-94.1%$12.16M$580K-0.1910Short Interest ↑GOVXGeoVax Labs1.8438 of 5 stars$0.74-2.6%$8.88+1,099.3%-86.6%$12.09M$3.95M-0.3710News CoverageShort Interest ↑MTNBMatinas Biopharma1.3627 of 5 stars$1.71-27.5%N/AN/A$12.01MN/A-0.3530Positive NewsShort Interest ↓Gap DownHigh Trading VolumeSNPXSynaptogenixN/A$8.40-8.6%N/A+85.6%$11.68MN/A-0.834TAOXSynaptogenixN/A$8.34-0.7%N/AN/A$11.67MN/A-0.414Earnings ReportGap DownLGVNLongeveron3.5195 of 5 stars$0.81+6.4%$7.25+796.2%-64.3%$11.54M$2.39M-0.1320Analyst RevisionSONNSonnet BioTherapeutics2.7933 of 5 stars$3.35-5.4%$20.00+497.0%-44.1%$11.21M$20K0.0010IXHLIncannex Healthcare0.2604 of 5 stars$0.40+5.2%N/A-77.2%$11.19M$10K-0.333Short Interest ↑Gap Down Related Companies and Tools Related Companies iBio Competitors Carisma Therapeutics Competitors Ernexa Therapeutics Competitors GeoVax Labs Competitors Matinas Biopharma Competitors Synaptogenix Competitors Synaptogenix Competitors Longeveron Competitors Sonnet BioTherapeutics Competitors Incannex Healthcare Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIVI) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access